Viberzi denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Viberzi
## Why Cigna May Deny Viberzi as Duplicate Therapy
A duplicate-therapy denial means Cigna's clinical review determined that another drug already on your active medication profile serves the same therapeutic purpose as Viberzi (eluxadoline) for irritable bowel syndrome with diarrhea (IBS-D). This denial type is common when a patient is concurrently approved for an antidiarrheal or another IBS-D agent, leading the plan's automated system to flag the request as redundant.
This denial is worth appealing because Viberzi works through a distinct mechanism — acting locally in the gut on mu- and kappa-opioid receptors — that is different from most over-the-counter or other prescription antidiarrheal approaches. Your prescriber is in the best position to explain why the existing therapy is inadequate or serves a different clinical purpose.
## Your Federal Appeal Rights
Under ACA §2719 (for non-grandfathered group and individual plans), you are entitled to an internal appeal followed by an independent external review if the internal appeal fails. Under ERISA §503, employer self-funded plans must provide a full-and-fair review with access to the criteria used. You generally have approximately four months from the denial notice to request external review. An expedited review is available if waiting for the standard timeline would seriously jeopardize your health or your ability to receive ongoing treatment.
## The Appeal Process
1. Request the denial rationale in writing. Ask for the specific clinical coverage policy Cigna applied and the exact criterion triggering the duplicate-therapy flag. 2. Internal appeal (Level 1). Submit a written appeal within the timeframe stated on your denial letter (typically 180 days). Include all supporting documentation. 3. External review. If the internal appeal is denied, file for independent external review — an accredited Independent Review Organization will evaluate whether the denial was clinically appropriate.
## Documentation to Gather
- Diagnosis confirmation: Chart notes, endoscopy or diagnostic records confirming IBS-D.
- Prior treatment history: Dates, doses, and documented outcomes of every IBS-D treatment tried, including the agent Cigna claims is duplicative.
- Clinical distinction letter: A letter from your prescriber explaining the mechanistic or clinical reason Viberzi is not duplicative of the flagged therapy — including why the current regimen is insufficient.
- Current symptom severity: Recent chart entries documenting frequency, severity, and functional impact of ongoing diarrhea episodes.
## Criteria-Mapping Structure
Request Cigna's current medical coverage policy for Viberzi. Copy each listed criterion into a simple table, then document the specific chart fact that satisfies it. Pay particular attention to any language about therapeutic alternatives — your prescriber's letter should directly address each alternative Cigna identifies and explain its clinical inadequacy for your case. Cite the FDA-approved prescribing information and the applicable gastroenterology society guidelines to support the clinical distinction.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →